Cargando…

Emergence of the CD226 Axis in Cancer Immunotherapy

In recent years, a set of immune receptors that interact with members of the nectin/nectin-like (necl) family has garnered significant attention as possible points of manipulation in cancer. Central to this axis, CD226, TIGIT, and CD96 represent ligand (CD155)-competitive co-stimulatory/inhibitory r...

Descripción completa

Detalles Bibliográficos
Autores principales:	Conner, Michael, Hance, Ken W., Yadavilli, Sapna, Smothers, James, Waight, Jeremy D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9263721/ https://www.ncbi.nlm.nih.gov/pubmed/35812451 http://dx.doi.org/10.3389/fimmu.2022.914406

Ejemplares similares

TIGIT-CD226-PVR axis: advancing immune checkpoint blockade for cancer immunotherapy
por: Chiang, Eugene Y, et al.
Publicado: (2022)

Hitting the complexity of the TIGIT-CD96-CD112R-CD226 axis for next-generation cancer immunotherapy
por: Jin, Hyung-seung, et al.
Publicado: (2021)

CD226 and TIGIT Cooperate in the Differentiation and Maturation of Human Tfh Cells
por: Yasutomi, Motoko, et al.
Publicado: (2022)

CD226: An Emerging Role in Immunologic Diseases
por: Huang, Zhiyi, et al.
Publicado: (2020)

TIGIT/CD226 Axis Regulates Anti-Tumor Immunity
por: Yeo, Jinah, et al.
Publicado: (2021)

CD226 Attenuates Treg Proliferation via Akt and Erk Signaling in an EAE Model
por: Wang, Ning, et al.
Publicado: (2020)

Imbalance of the CD226/TIGIT Immune Checkpoint Is Involved in the Pathogenesis of Primary Biliary Cholangitis
por: Deng, Chuiwen, et al.
Publicado: (2020)

CD226 identifies functional CD8(+)T cells in the tumor microenvironment and predicts a better outcome for human gastric cancer
por: Huang, Hao, et al.
Publicado: (2023)

TIGIT can inhibit T cell activation via ligation-induced nanoclusters, independent of CD226 co-stimulation
por: Worboys, Jonathan D., et al.
Publicado: (2023)

Increased Proportion of CD226(+) B Cells Is Associated With the Disease Activity and Prognosis of Systemic Lupus Erythematosus
por: Nakano, Miki, et al.
Publicado: (2021)

CD226 Deletion Reduces Type 1 Diabetes in the NOD Mouse by Impairing Thymocyte Development and Peripheral T Cell Activation
por: Shapiro, Melanie R., et al.
Publicado: (2020)

B7-H3/CD276: An Emerging Cancer Immunotherapy
por: Zhou, Wu-Tong, et al.
Publicado: (2021)

Human CD4(+)CD25(+)CD226(-) Tregs Demonstrate Increased Purity, Lineage Stability, and Suppressive Capacity Versus CD4(+)CD25(+)CD127(lo/-) Tregs for Adoptive Cell Therapy
por: Brown, Matthew E., et al.
Publicado: (2022)

Expression of the Inhibitory Receptor TIGIT Is Up-Regulated Specifically on NK Cells With CD226 Activating Receptor From HIV-Infected Individuals
por: Yin, Xiaowan, et al.
Publicado: (2018)

Glioblastoma Immunotherapy Targeting the Innate Immune Checkpoint CD47-SIRPα Axis
por: Hu, Jinyang, et al.
Publicado: (2020)

Treg-Specific CD226 Deletion Reduces Diabetes Incidence in NOD Mice by Improving Regulatory T-Cell Stability
por: Thirawatananond, Puchong, et al.
Publicado: (2023)

Upregulation of the CD155-CD226 Axis Is Associated With Muscle Inflammation and Disease Severity in Idiopathic Inflammatory Myopathies
por: Li, Wenli, et al.
Publicado: (2023)

CD226 ligation protects against EAE by promoting IL-10 expression via regulation of CD4(+) T cell differentiation
por: Zhang, Rong, et al.
Publicado: (2016)

Increased levels of soluble CD226 in sera accompanied by decreased membrane CD226 expression on peripheral blood mononuclear cells from cancer patients
por: Xu, Zhuwei, et al.
Publicado: (2009)

Inhibition of the CD47-SIRPα axis for cancer therapy: A systematic review and meta-analysis of emerging clinical data
por: Son, Ji, et al.
Publicado: (2022)

Editorial: CD4(+) T Cells in Cancer Immunotherapies
por: González-Navajas, José M., et al.
Publicado: (2021)

Perturbed CD8(+) T cell TIGIT/CD226/PVR axis despite early initiation of antiretroviral treatment in HIV infected individuals
por: Tauriainen, Johanna, et al.
Publicado: (2017)

The CD226/TIGIT axis is involved in T cell hypo-responsiveness appearance in long-term kidney transplant recipients
por: Del Bello, Arnaud, et al.
Publicado: (2022)

CD73's Potential as an Immunotherapy Target in Gastrointestinal Cancers
por: Harvey, Jerry B., et al.
Publicado: (2020)

RUNX1/CD44 axis regulates the proliferation, migration, and immunotherapy of gliomas: A single-cell sequencing analysis
por: Zhang, Hao, et al.
Publicado: (2023)

Emerging roles of the gut microbiota in cancer immunotherapy
por: Shi, Zhuangzhuang, et al.
Publicado: (2023)

The Natural Killer–Dendritic Cell Immune Axis in Anti-Cancer Immunity and Immunotherapy
por: Peterson, Erin E., et al.
Publicado: (2021)

Targeting the dendritic cell-T cell axis to develop effective immunotherapies for glioblastoma
por: Gardam, Bryan, et al.
Publicado: (2023)

Altered expression of CD226 and CD96 on natural killer cells in patients with pancreatic cancer
por: Peng, Yun-Peng, et al.
Publicado: (2016)

Next Generation CD40 Agonistic Antibodies for Cancer Immunotherapy
por: Salomon, Ran, et al.
Publicado: (2022)

Expression of CD226 is associated to but not required for NK cell education
por: Wagner, Arnika K., et al.
Publicado: (2017)

Inflammasomes: Emerging Central Players in Cancer Immunology and Immunotherapy
por: Karan, Dev
Publicado: (2018)

Immunosuppressive adenosine-targeted biomaterials for emerging cancer immunotherapy
por: Wei, Qi, et al.
Publicado: (2022)

Editorial: Emerging talents in cancer immunity and immunotherapy: 2022
por: Maeurer, Markus
Publicado: (2023)

Inhibitors of the CD73-adenosinergic checkpoint as promising combinatory agents for conventional and advanced cancer immunotherapy
por: Kurago, Zoya, et al.
Publicado: (2023)

Potential Role of CD47-Directed Bispecific Antibodies in Cancer Immunotherapy
por: Yang, Yan, et al.
Publicado: (2021)

Targeting the CCL2/CCR2 Axis in Cancer Immunotherapy: One Stone, Three Birds?
por: Fei, Liyang, et al.
Publicado: (2021)

Protein Arginine Methylation: An Emerging Modification in Cancer Immunity and Immunotherapy
por: Dai, Weijing, et al.
Publicado: (2022)

PSGL-1 Immune Checkpoint Inhibition for CD4(+) T Cell Cancer Immunotherapy
por: DeRogatis, Julia M., et al.
Publicado: (2021)

New tricks for old targets: Anti-CTLA-4 antibodies re-envisioned for cancer immunotherapy
por: Waight, Jeremy D., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_8urlmgbs0fjloecebacpgk2lvb